Market Overview

Benzinga's Top Upgrades

Share:
Benzinga's Top Upgrades
Related BIIB
Benzinga's Bulls & Bears Of The Week: Bristol-Myers, GE, Target, Under Armour And More
Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs
Related REGN
Canaccord Slices Regeneron Price Target 32% On Eylea, Dupixent Challenges
Benzinga's Top Upgrades, Downgrades For February 21, 2018
Orbimed Advisors Llc Buys Regeneron Pharmaceuticals Inc, Amicus Therapeutics Inc, Loxo Oncology ... (GuruFocus)

Analysts at Citigroup upgraded Biogen Idec (NASDAQ: BIIB) from “neutral” to “buy.” The target price for Biogen Idec is set to $236. Biogen Idec's shares closed at $215.20 on Friday.

Analysts at Piper Jaffray upgraded Regeneron Pharmaceuticals (NASDAQ: REGN) from “neutral” to “overweight.” The target price for Regeneron Pharmaceuticals is set to $274. Regeneron's shares closed at $224.88 on Friday.

Analysts at Morgan Stanley upgraded Whitewave Foods (NYSE: WWAV) from “equal-weight” to “overweight.” The target price for Whitewave Foods is set to $19. Whitewave's shares closed at $16.25 on Friday.

BMO Capital upgraded First Majestic Silver (NYSE: AG) from “market perform” to “outperform.” The target price for First Majestic Silver has been lowered from $18 to $13. First Majestic Silver's shares closed at $10.59 on Friday.

Latest Ratings for BIIB

DateFirmActionFromTo
Feb 2018ArgusDowngradesBuyHold
Feb 2018MizuhoMaintainsBuyBuy
Jan 2018UBSUpgradesNeutralBuy

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: top upgradesUpgrades Analyst Ratings

 

Related Articles (BIIB + AG)

View Comments and Join the Discussion!